Bank of New York Mellon Corp Has $835,000 Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Bank of New York Mellon Corp lessened its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 6.7% during the 4th quarter, Holdings Channel.com reports. The fund owned 98,547 shares of the specialty pharmaceutical company’s stock after selling 7,064 shares during the period. Bank of New York Mellon Corp’s holdings in KalVista Pharmaceuticals were worth $835,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in KALV. China Universal Asset Management Co. Ltd. raised its holdings in shares of KalVista Pharmaceuticals by 24.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock valued at $87,000 after purchasing an additional 2,043 shares in the last quarter. SG Americas Securities LLC increased its position in KalVista Pharmaceuticals by 10.0% during the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after buying an additional 1,319 shares during the last quarter. Hennion & Walsh Asset Management Inc. bought a new position in KalVista Pharmaceuticals during the fourth quarter valued at about $634,000. JPMorgan Chase & Co. lifted its position in shares of KalVista Pharmaceuticals by 8.0% in the third quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company’s stock worth $262,000 after buying an additional 1,670 shares during the last quarter. Finally, Barclays PLC increased its holdings in shares of KalVista Pharmaceuticals by 418.5% during the 3rd quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock valued at $778,000 after acquiring an additional 54,257 shares during the last quarter.

KalVista Pharmaceuticals Trading Up 2.0 %

Shares of KALV stock opened at $12.50 on Wednesday. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.30 and a 1 year high of $15.50. The firm’s fifty day simple moving average is $10.32 and its 200 day simple moving average is $10.23. The firm has a market capitalization of $621.45 million, a P/E ratio of -3.43 and a beta of 0.76.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par purchased 14,562 shares of the stock in a transaction on Monday, February 3rd. The shares were purchased at an average price of $9.22 per share, with a total value of $134,261.64. Following the acquisition, the insider now directly owns 5,012,796 shares of the company’s stock, valued at $46,217,979.12. This represents a 0.29 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Benjamin L. Palleiko sold 5,104 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total transaction of $50,121.28. Following the completion of the transaction, the chief executive officer now directly owns 278,855 shares of the company’s stock, valued at $2,738,356.10. This trade represents a 1.80 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have purchased 236,055 shares of company stock worth $2,162,146 and have sold 17,292 shares worth $184,625. Insiders own 10.50% of the company’s stock.

Analyst Upgrades and Downgrades

KALV has been the subject of a number of recent analyst reports. Bank of America assumed coverage on KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They set a “buy” rating and a $22.00 target price for the company. Citizens Jmp raised shares of KalVista Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 31st. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. JMP Securities began coverage on shares of KalVista Pharmaceuticals in a report on Friday, January 31st. They set an “outperform” rating and a $19.00 price target for the company. Finally, TD Cowen initiated coverage on KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, KalVista Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $23.80.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).